Skip to main content
OpenTrials
Completed

NCT Number: NCT05062343

Cook Balloon vs Dilapan-S for Outpatient Cervical Ripening

The goal of this study is to compare Cook balloon and Dilapan-S for outpatient cervical ripening to see if Dilapan-S is non-inferior in increasing Bishop score compared to the Cook balloon.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–50 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Brigham and Women's HospitaL

Boston, Massachusetts, 02115, United States

About this study

Upon presentation for cervical ripening appointment, a sterile vaginal exam will be completed to assign Bishop score, as per standard routine. Once the patient has been consented and randomized, the participant will have a Cook catheter or Dilapan-S inserted. For the Cook catheter, the uterine component of the balloon will be inflated to maximum 60mL, the vaginal balloon will not be inflated per standard practice and per the literature that shows slightly increased pain and negligible improvement in cervical ripening. The catheter will be taped to the inner thigh with gentle traction. For Dilapan-S, 3-5 dilators will be placed.

After placement, the patient will be discharged home with strict return precautions per the outpatient cervical ripening protocol. Patients must return to labor and delivery within 24 hours of cervical ripening agent placement at their scheduled inpatient induction time.

Upon return to labor and delivery, if not already expelled, the mechanical ripening device will be removed, and an examiner blinded to the cervical ripening method will complete a sterile vaginal exam to assign a Bishop score.

At that point health care providers will manage active labor per usual practice. Labor interventions are at the discretion of the healthcare provider. The need for operative delivery or cesarean section will be at the discretion of the healthcare provider.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18-50 years of age
  • Term (37-41 6/7 weeks gestational age)
  • Low risk (i.e. without any maternal or fetal co-morbidity) and who are candidates for outpatient cervical ripening per the Brigham and Women's outpatient cervical ripening protocol
  • Singleton pregnancy
  • Cephalic presentation

Exclusion criteria

  • Prior cesarean section
  • Any contraindication to outpatient cervical ripening per Brigham and Women's outpatient cervical ripening protocol
  • Non-English-speaking

Treatment and study plan

Dilapan-S

Device

Osmotic dilator

Cook Cervical Ripening Balloon

Device

Double balloon catheter for cervical ripening

Other names: Cook catheter

Primary outcomes

  1. Change in Bishop Score

    Time frame: Up to 24 hours

    Difference in Bishop score calculated from exam at time of device removal minus Bishop score calculated from exam at time of device placement. Bishop score, or cervical score, ranges from a minimum of 0 to maximum of 13. Higher scores indicate that the cervix is more favorable, or ready for labor. Thus, change in Bishop score could range from -13 to +13 with a higher number showing more change in the score, or more cervical ripening.

Secondary outcomes

  1. Patient Satisfaction

    Time frame: Assessed upon device removal, within 24 hours

    Patient Satisfaction score based on patient survey. Range from 0 (unsatisfied) to 10 (highly satisfied).

  2. Mode of Delivery: Vaginal Delivery, Cesarean Delivery

    Time frame: Assessed at the time of delivery, within 1 week

    Mode of delivery, vaginal (including spontaneous vaginal, forceps and vacuum) and cesarean delivery

  3. Time on Labor and Delivery

    Time frame: Assessed at the time of delivery, within 1 week

    Time from admission on labor and delivery until delivery. Measured in hours.

  4. Maternal Length of Stay

    Time frame: Assessed at end of study period (week 4)

    Admission Date/Time to Discharge Date/Time

  5. Cervical Ripening Success Score: No Failure, Failure

    Time frame: Assessed at the time of device removal, within 24 hours

    Failure defined by: inability to place intervention agent or need for further cervical ripening after removal

  6. Composite Maternal Morbidity: Morbidity, no Morbidity

    Time frame: Assessed at end of study period (week 4)

    Morbidity defined as any one of the following: higher-order laceration, blood transfusion, endometritis, wound infection, venous thromboembolism, hysterectomy, ICU admission or death

  7. Composite Neonatal Morbidity: Morbidity, no Morbidity

    Time frame: Assessed at end of study period (week 4)

    Morbidity defined as any one of the following: culture-proven neonatal sepsis, neonatal blood transfusion, hypoxic-ischemic encephalopathy, intraventricular hemorrhage grade 3 or 4, or therapeutic hypothermia

Sponsors and collaborators

Lead sponsor

Brigham and Women's Hospital

Other

Registry information

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Sep 30, 2021
Registry last updated
Oct 27, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.